CORDIS Project
Funding breakdown and partner intelligence are Premium
Sign in and upgrade to Premium for EU contribution totals, consortium analytics, OpenAlex research context, and AI summaries. · 0 consortium intelligence fields visible of 1
Start free • Cancel anytime • 14-day refund guarantee
This project focuses on understanding the role of leukemic stem cells in acute myeloid leukemia, particularly during minimal residual disease. By utilizing advanced single-cell technologies, the research aims to identify and characterize these resistant cells to improve treatment strategies and prevent relapse.
Acute myeloid leukemia (AML) is one of the most aggressive and deadliest cancers with frequent relapse.
Although initial therapies eliminate most AML blast cells, rare cells with leukemic stem cell (LSC) activity can persist and likely generate minimal residual disease (MRD) to re-initiate AML.
Thus, targeting resistant LSCs during MRD might provide a unique opportunity to prolong remission and prevent relapse.
However, because it is notoriously challenging to identify rare LSCs present within t…
DEUTSCHES KREBSFORSCHUNGSZENTRUM HEIDELBERG
Partner organizations (coordinator is shown above), with normalized type and CORDIS activity type. Guests see up to 4 partners.
Similar projects, consortium collaboration history, frequent partners, and OpenAlex research context.
Guests see up to 5 EuroSciVoc fields.
Guests see up to 5 topics.
Guests see up to 5 keywords.
